BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 18473731)

  • 61. Animal models for development of therapeutic HPV16 vaccines (review).
    Bubeník J
    Int J Oncol; 2002 Jan; 20(1):207-12. PubMed ID: 11743666
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV).
    Movahed F; Darzi S; Mahdavi P; Salih Mahdi M; Qutaiba B Allela O; Naji Sameer H; Adil M; Zarkhah H; Yasamineh S; Gholizadeh O
    Virol J; 2024 May; 21(1):124. PubMed ID: 38822328
    [TBL] [Abstract][Full Text] [Related]  

  • 63. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
    Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
    Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
    Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
    PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7.
    Oosterhuis K; Ohlschläger P; van den Berg JH; Toebes M; Gomez R; Schumacher TN; Haanen JB
    Int J Cancer; 2011 Jul; 129(2):397-406. PubMed ID: 21207427
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers.
    Lescaille G; Pitoiset F; Macedo R; Baillou C; Huret C; Klatzmann D; Tartour E; Lemoine FM; Bellier B
    Hum Gene Ther; 2013 May; 24(5):533-44. PubMed ID: 23521528
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapeutic vaccines for high-risk HPV-associated diseases.
    Chabeda A; Yanez RJR; Lamprecht R; Meyers AE; Rybicki EP; Hitzeroth II
    Papillomavirus Res; 2018 Jun; 5():46-58. PubMed ID: 29277575
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Human papillomavirus vaccines for the treatment of cervical cancer.
    Sin JI
    Expert Rev Vaccines; 2006 Dec; 5(6):783-92. PubMed ID: 17184217
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
    Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
    Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer.
    Sharma C; Khan MA; Mohan T; Shrinet J; Latha N; Singh N
    Immunol Res; 2014 Jan; 58(1):132-8. PubMed ID: 24174302
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009.
    Pellom ST; Smalley Rumfield C; Morillon YM; Roller N; Poppe LK; Brough DE; Sabzevari H; Schlom J; Jochems C
    JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33651712
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
    Komatsu A; Igimi S; Kawana K
    Vaccine; 2018 Jun; 36(24):3423-3426. PubMed ID: 29735324
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
    Hasan Y; Furtado L; Tergas A; Lee N; Brooks R; McCall A; Golden D; Jolly S; Fleming G; Morrow M; Kraynyak K; Sylvester A; Arif F; Levin M; Schwartz D; Boyer J; Skolnik J; Esser M; Kumar R; Bagarazzi M; Weichselbaum R; Spiotto M
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):487-498. PubMed ID: 32151670
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Anti-tumor effects of genetic vaccines against HPV major oncogenes.
    Cordeiro MN; Paolini F; Massa S; Curzio G; Illiano E; Duarte Silva AJ; Franconi R; Bissa M; Morghen Cde G; de Freitas AC; Venuti A
    Hum Vaccin Immunother; 2015; 11(1):45-52. PubMed ID: 25483514
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients.
    Achour M; Kahla S; Zeghal D; Kochbati L; Mongi M; Zouari F; Oueslati R
    Viral Immunol; 2009 Feb; 22(1):7-16. PubMed ID: 19210223
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
    Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
    Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.